drug
TALVEY
updated 6mo agoby Janssen Biotech Inc
community read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
News(9)
- At ASH, drugmakers to showcase early data for three-pronged cancer therapiesJ&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.biopharma_dive · 14d ago
- Novartis wagers almost $8B on a Chinese biotech’s RNA drugsIn exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.biopharma_dive · 1mo ago
- GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750MAfter inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.biospace · 2mo ago
- GSK doubles down on Chimagen with $750M multiple myeloma wagerGSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The de…fiercebiotech · 2mo ago
- Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointA pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multip…fiercebiotech · 2mo ago
- Legend Biotech CEO abruptly steps down without permanent replacementIn a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.fiercebiotech · 3mo ago
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.biopharma_dive · 3mo ago
- J&J multiple myeloma drug gains edge in earlier stage diseaseThe latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.biopharma_dive · 5mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that